Oppenheimer lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $15 from $20 and keeps an Outperform rating on the shares. The firm notes Y-mAbs Therapeutics hosted an R&D call to discuss the latest on its SADA platform, and, Oppenheimer had hoped, detail on new targets and plans to expand clinical studies for the platform. Management provided a deep dive on data from the GD2 Phase 1 Part A study, highlighting a consistent PK profile for the SADA component, but limited tumor retention for Lu177-Dota. As a result, Y-mAbs plans a bridging study to incorporate an alternative, and based on preclinical data, significantly improved, isotope carrier.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-Mabs Therapeutics: Buy Rating Affirmed on Promising SADA Program Advancements and Market Expansion Potential
- Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics
- Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline
- Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress
- Y-mAbs Therapeutics price target lowered to $11 from $12 at H.C. Wainwright